ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1247

Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators

Lucas Adams1, Carla J. Guthridge1, Tim Gross1, Hua Chen1, Krista M. Bean1, Virginia C. Roberts1, Julie M. Robertson2, Melissa E. Munroe1, Joel M. Guthridge3, Roger Montgomery4, M. Sohail Khan4, Fabio Mota5, Michael Peercy6, Bobby Saunkeah7 and Judith A. James8,9, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Acelity, San Antonio, TX, 3Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Cherokee Nation Health Services, Tahlequah, OK, 5Chickasaw Nation Medical Center, Ada, OK, 6Epidemiology, Chickasaw Nation Department of Health, Ada, OK, 7Chickasaw Nation Department of Health, Ada, OK, 8Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, cytokines, diagnostic criteria and rheumatoid arthritis, pathogenesis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Healthcare Disparities in Rheumatology - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Diagnosis of RA is difficult in American Indian (AI) patients who often have atypical autoantibodies (e.g. ANA) with erosive arthritis. Soluble mediators may serve as alternative markers for earlier identification of RA from other conditions affecting AI patients. This study characterized soluble mediator profiles of AI RA patients to identify pathogenic mechanisms of disease and develop early diagnostic algorithms for use by healthcare providers to direct patients toward individualized therapies.

Methods: The serum levels of RF, anti-CCP, and 26 soluble mediators from AI patients with RA (n=59), arthralgias (n=28), polyarthritis/osteoarthritis (n=31), or AI healthy controls (n=116) were measured using ELISA or multiplex assays. Comparisons were made using Kruskal-Wallis testing with Dunn’s multiple comparison. To identify factors that distinguished AI RA patients from healthy controls or patients with other forms of arthritis, random forest modeling was performed using autoantibodies and soluble mediators that differed significantly between the groups. One model used autoantibodies, a second used soluble mediators and a third used both to classify AI RA patients from other AI arthritis groups. Each model was developed using 300 trees, √x variables at each split (where x=number of incorporated variables), and a terminal node size of 1. Top predictive classifiers were identified using the prediction step of VSURF function in R 3.3.0. Sensitivity, specificity, positive and negative predictive values were calculated based on 50 random forests using the top predictive identifiers for each model.

Results: When comparing AI RA patients and controls, the soluble mediator model outperformed the autoantibody model with an accuracy of 93.2% vs 88.1%. The combined model outperformed the autoantibody model with an accuracy of 92.7%. IL-8, TGF-beta, SCF, MCP-3, and IL-1RA were identified as the top predictive classifiers when using the soluble mediator model. IL-8, RF(IgM), anti-CCP, and TGF-beta were identified as the top predictive classifiers when using the combined model. When comparing RA patients to AI patients from other arthritis groups the combined model outperformed the autoantibody model (82.5% vs 78.3%) with anti-CCP, RF (IgM), SCF, resistin, and TNFRII as top predictive classifiers. The soluble mediator model did not differentiate patients with RA from the other arthritis groups, suggesting some AI patients with polyarthritis have similar immune dysfunction without meeting classification criteria. IL-8 levels best distinguished patients and controls and SCF levels best distinguished RA patients from other diseases.

Conclusion: Adding soluble mediators to traditional autoantibodies improves the accuracy of diagnostic modeling in AI RA patients when compared to AI controls or AI patients with other forms of arthritis. These data support the hypothesis that soluble mediator profiles of AI RA patients can be used to identify mechanisms of disease and to develop early diagnostic algorithms for use by healthcare providers to direct patients toward individualized therapies. The study was funded by Native American Research Centers for Health.


Disclosure: L. Adams, None; C. J. Guthridge, None; T. Gross, None; H. Chen, None; K. M. Bean, None; V. C. Roberts, None; J. M. Robertson, None; M. E. Munroe, None; J. M. Guthridge, None; R. Montgomery, None; M. S. Khan, None; F. Mota, None; M. Peercy, None; B. Saunkeah, None; J. A. James, None.

To cite this abstract in AMA style:

Adams L, Guthridge CJ, Gross T, Chen H, Bean KM, Roberts VC, Robertson JM, Munroe ME, Guthridge JM, Montgomery R, Khan MS, Mota F, Peercy M, Saunkeah B, James JA. Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/diagnostic-modeling-of-rheumatoid-arthritis-in-oklahoma-tribal-members-using-soluble-mediators/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-modeling-of-rheumatoid-arthritis-in-oklahoma-tribal-members-using-soluble-mediators/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology